Safety and immunogenicity of a ChAdOx1 vaccine against Rift Valley fever in UK adults: an open-label, non-randomised, first-in-human phase 1 clinical trial

https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(23)00068-3/fulltext?dgcid=hubspot_update_feature_updatealerts_laninf&utm_campaign=update-laninf&utm_medium=email&_hsmi=269495838&_hsenc=p2ANqtz-8xkZVKbAmgQ5J-hB__rEeKHsVJgl2HdOj1Ti0uLFLnns4VDUPeYt1zjPJp1_AALWseXEJo8CRXoqRH1aODyfliRwQvDg&utm_content=269473818&utm_source=hs_email